Heidelberg Pharma AG

Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024

Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024

Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024

Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient

Heidelberg Pharma AG Announces Updated Guidance

Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024